Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Silence Therapeutics Plc/ 10-Q

Quarterly Report · 10-Q

Silence Therapeutics Plc

SLNCFOTCEQUITYCurrent

Quarterly Report

Filed Aug 10, 2026Accepted Aug 10, 2026, 7:26 AM EDTCIK 1479615Accession 0001193125-26-341248
View company →Permanent SEC source ↗
Share

Company context

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit https://www.silence-therapeutics.com/.

Current securities

SLNNASDAQ · ADR · CurrentSLNCFOTC · EQUITY · Current

Recent company filings

  1. DEFA14A filingOct 19, 2026
  2. DEFA14A filingOct 19, 2026
  3. Entry into a Material Definitive Agreement · Regulation FD DisclosureOct 19, 2026
  4. SCHEDULE 13D/A - filed by Griffiths Richard Ian regarding Silence Therapeutics plcAug 13, 2026
  5. Entry into a Material Definitive Agreement · Other EventsAug 12, 2026

Registered securities in this filing

Silence Therapeutics plc · 10-Q · Filed 2026-08-10

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Ordinary Share, nominal value £0.05 per share

Symbol
No trading symbol declared
Exchange
NASDAQ
Classification
COMMON
Filing context

Context: C_875120f2-2165-47ec-80e8-ea8af45db99f

Dimensions: us-gaap:StatementClassOfStockAxis

No-trading-symbol fact: true

American Depositary Shares, each representing three ordinary shares, nominal value £0.05 per share

Symbol
SLN
Exchange
NASDAQ
Classification
ADS
Status
Current
Filing context

Context: C_fc2a9bcd-f1a1-418a-8dec-167422308189

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000119312526341248 · 2 registered-security cover members

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.